Properties of regulatory B cells regulating B cell targets

Qiang Fu,Kang Mi Lee,Guoli Huai,Kevin Deng,Divyansh Agarwal,Charles G. Rickert,Noel Feeney,Rudy Matheson,Hongji Yang,Christian LeGuern,Shaoping Deng,James F. Markmann
DOI: https://doi.org/10.1111/ajt.16772
IF: 9.369
2021-09-06
American Journal of Transplantation
Abstract:Regulatory B cells (Bregs) have shown promise as anti-rejection therapy applied to organ transplantation. However, less is known about their effect on other B cell populations that are involved in chronic graft rejection. We recently uncovered that naïve B cells, stimulated by TLR ligand agonists, converted into B cells with regulatory properties (Bregs-TLR) that prevented allograft rejection. Here we examine the granular phenotype and regulatory properties of Bregs-TLR cells suppressing B cells. Co-cultures of Bregs-TLR with LPS-activated B cells showed a dose-dependent suppression of targeted B cell proliferation. Adoptive transfers of Bregs-TLR induced a decline in antibody responses to antigenically disparate skin grafts. The role of Breg BCR specificity in regulation was assessed using B cell deficient mice replenished with transgenic BCR (OB1) and TCR (OTII) lymphocytes of matching antigenic specificity. Results indicated that proliferation of OB1 B cells, mediated through help from CD4+ OTII cells, was suppressed by OB1 Bregs of similar specificity. Transcriptomic analyses indicated that Bregs-TLR suppression is associated with a block in targeted B cell differentiation controlled by PRDM1 (Blimp1). This work uncovered the regulatory properties of a new brand of Breg cells and provided mechanistic insights on potential applications of Breg therapy in transplantation.
surgery,transplantation
What problem does this paper attempt to address?